Fate Therapeutics, Inc.

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To produce better cell therapies, we use human induced pluripotent stem cells (iPSCs) generated from our proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. We can direct and determine the fate of our clonal master iPSC lines to produce well-defined and uniformly composed NK- and T-cell products.